The ability of integrin adhesion receptors to undergo rapid changes in affinity for their extracellular ligands (integrin activation) is essential for the development and function of multicellular animals and is dependent on interactions between the integrin β subunit cytoplasmic tail and the cytoskeletal protein talin. Crosstalk between different integrins and between integrins and other receptors impacts many cellular processes including adhesion, spreading, migration, clot retraction, proliferation and differentiation. One form of integrin cross-talk, trans-dominant inhibition of integrin activation, occurs when ligand binding to one integrin inhibits the activation of a second integrin. This may be clinically relevant in a number of settings such as during platelet adhesion, leukocyte transmigration and angiogenesis. Here we report that competition for talin underlies trans-dominant inhibition of integrin activation. This conclusion is based on our observations that (i) β tails selectively defective in talin binding are unable to mediate trans-dominant inhibition, (ii) trans-dominant inhibition can be reversed by overexpression of integrin-binding and activating fragments of talin, and (iii) expression of another non-integrin talin-binding protein, PIPKIγ-90, also inhibits integrin activation.
Introduction
Integrin adhesion receptors are essential for the development and survival of multicellular animals. An important feature of integrins is their ability to undergo rapid changes in affinity for extracellular ligand, a process referred to as inside-out signaling or integrin activation (1) (2) (3) . Integrin activation is under the control of signals from within the cell and regulates cell adhesion, migration, and assembly of an extracellular matrix (4;5) . Tight control of integrin activation is required for many biological processes including embryonic development, wound healing, hemostasis, the immune response and tumor cell metastasis (6) (7) (8) .
Most cells express more than one integrin and cross-talk between integrins allows ligand binding to one integrin to regulate the function of other integrins on the same cell (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . One form of integrin cross-talk occurs when ligation of one integrin inhibits the activation of a second integrin, so called trans-dominant inhibition of integrin activation (9) . Trans-dominant inhibition mediated by β1, β2 or β3 integrins has been demonstrated in a variety of cell types and shown to regulate cell adhesion, spreading, migration, clot retraction and differentiation (9;10;14;18;20) . Trans-dominant integrin inhibition may be physiologically and clinically relevant in a number of settings. For example, α2β1-dependent platelet adhesion to collagen is inhibited following αIIbβ3-mediated fibrinogen binding to ADP-activated platelets (14) , and this may contribute to increased platelet adhesion to the subendothelium in Glanzmann's thrombastenia and afibrinogenemia (14) . Furthermore, in patients with acute coronary syndrome, transdominant inhibition of α2β1 may underlie the significant long-term reduction of clinical events following short-term treatment with pharmacological αIIbβ3 inhibitors (14) .
by guest on November 6, 2017 http://www.jbc.org/ Downloaded from Trans-dominant inhibition also regulates adhesion of human T-lymphocytes and so contributes to control of leukocyte transmigration (10) . In addition, there is now considerable interest in whether αvβ3-mediated trans-dominant inhibition of α5β1 accounts for the effects of endogenous or pharmaceutical antagonists of αvβ3 on tumor angiogenesis (19;21;22) .
Despite its potential importance, the mechanism of trans-dominant integrin inhibition has not been elucidated. It is, however, known that inhibition is dependent on the β subunit cytoplasmic tail of the suppressive integrin (9) . Furthermore, expression of isolated integrin β tails, fused to an irrelevant type I transmembrane and cytoplasmic domain, in a variety of cell lines, megakaryocytes, platelets, and in the thymus and cardiac tissue in vivo, is sufficient to induce trans-dominant integrin inhibition (20;23-31) . One explanation for trans-dominant inhibition is that the suppressive β tail competes with other integrin β tails for limiting cytoplasmic factors necessary for integrin activation (23;26) . Thus, trans-dominant integrin inhibition may be mediated by the titration of essential intracellular protein(s).
Talin, a cytoskeletal protein, binds to most integrin β tails (32) , talin binding to the integrin β tail activates integrins (33) (34) (35) (36) , and disruption of the integrin-talin interaction prevents integrin activation (35) Thus, talin binding to integrin β tails is a final step in integrin activation. We therefore examined whether competition for talin mediates trans-dominant inhibition of integrin activation. We report that β tails containing mutations that selectively inhibit talin binding are unable to mediate transdominant integrin inhibition and that over-expression of the integrin β tail-binding domain of talin can reverse trans-dominant inhibition. 
Experimental Procedures
Antibodies and cDNAs. Monoclonal antibodies, anti-talin, 8d4 (Sigma), anti-HA, 12CA5
(American Type Culture Collection) anti-Tac, 7G7B6 (American Type Culture Collection), anti-β1 integrin, 9EG7 (Pharmingen) and anti-GFP (CLONTECH) were obtained commercially. The anti-αIIbβ3 monoclonal antibodies PAC-1 and anti-LIBS6, the anti-β3 C-terminal peptide antiserum (8275) and the αIIbβ3 specific antagonist Ro43-5054 have been described previously (37) (38) (39) . cDNAs encoding Tac-α5, Tac-β3, mouse talin F2F3 (Residues 206-305; Swissprot entry TALI_MOUSE (P26039)), αIIb and β3 integrin tail model proteins, GFP-PIPKIγ-87, GFP-PIPKIγ-90, GFP-PIPKIγ-90(W647A) and GST-fibronectin type III repeats 9-11 (FN9-11) have been described previously (26;33;40-42) . Point mutations were introduced using the Quikchange site-directedmutagenesis kit (Stratagene) and confirmed by DNA sequencing.
Affinity chromatography with recombinant integrin tails. Recombinant integrin tail model proteins were produced and purified as previously described (43) . Talin was purified from outdated platelets and cell lysates were prepared as previously described (34;43) . Affinity chromatography was performed using recombinant integrin tails bound to His-Bind resin (Novagen) as previously described (34;43;44) . 5 µl of coated beads and 1 µg of purified talin was routinely used. Bound proteins were fractionated by SDS-PAGE and analyzed by western blotting. Cell spreading assays. CHO cells expressing αIIbβ3 were transiently transfected as described above, with cDNAs encoding Tac-α5, Tac-β3 or Tac-β3 mutants (2 µg) and EGFP (1 µg) as a marker of transfection. Twenty four hours later cells were plated onto tissue culture dishes coated with 15 µg/ml fibrinogen. Cells were allowed to spread for 1 h and viewed using a Zeiss Axiovert 100 epifluorescence microscope with a 10x objective. Bright-field and GFP images were images were collected on a SPOT chargecoupled device (CCD) camera (Diagnostic Instruments Inc., Sterling Heights, MI).
Images were processed and the area of GFP positive cells calculated using Scion Image Beta 4.0.2 software (Scion Corporation, Frederick, MD, http://www.scioncorp.com).
Results

Isolated β tails require an intact talin-binding site to mediate trans-dominant
inhibition of integrin αIIbβ3 activation. Integrin activation is inhibited by overexpression of integrin β3 tails fused to the transmembrane and extracellular domains of the Tac subunit of the interleukin-2 receptor (Tac-β3) (26) . To examine whether competition for talin mediates trans-dominant inhibition we generated Tac (Fig 2A) . Thus, mutations that disrupt talin binding inhibit trans-dominant suppression of αIIbβ3 by isolated β tails.
The activation index (the ratio of specific PAC-1 binding : maximal, anti-LIBS6-stimulated, specific PAC-1 binding) allows quantification of αIIbβ3 activation (45).
Tac-β3 or Tac-β3 containing mutations that maintain talin binding (D740A or D740K) produced a >60% inhibition of αIIbβ3 activation while Tac-β3 containing mutations that disrupt talin binding (W739A, L746A,K748A or L746A) had little effect on integrin activation (Fig 2B) . The differing effects of the Tac-β3 mutants were not due to differing expression levels as analyses were performed on cells gated for similar Tac expression.
Furthermore, western blotting of immunoprecipitated Tac-β3 revealed that all the Tac-β3 constructs reacted with an antiserum raised against the C-terminal portion of the β3 tail ( Fig 2C) suggesting that differential proteolysis of the Tac-β3 mutants does not account for their differing effects on integrin activation. Hence, free β3 tails require an intact talin-binding site to mediate trans-dominant inhibition of αIIbβ3. for talin also mediated trans-dominant inhibition of more active integrins we examined chimeric αIIbβ3 integrins. Substitution of the α5 cytoplasmic tail for that of αIIb generates a more active integrin αIIbα5β3 (37) (activation index 0.45 ± 0.03; mean ± SE). Tac-β3 inhibited the activation of this active chimera and this inhibition was impaired by mutations that reduce talin binding (Fig 3A) . Therefore talin binding to Tac-β3 is required for trans-dominant inhibition of β3 integrins regardless of their activation state. Furthermore, this effect is not limited to β3 integrins as similar results were obtained with active (activation index 0.40 ± 0.03) chimeric αIIbβ3 integrins containing the α6Aβ1A cytoplasmic domains (αIIbα6Aβ3β1A; Fig 3B) .
The experiments described above assessed the activation of ectopically expressed αIIbβ3 or chimeric αIIbβ3 integrins using the mAb PAC-1. As an alternative approach we used an integrin-binding fragment of fibronectin, composed of type III repeats 9-11 (FN9-11), to assess the activation state of endogenous CHO α5β1 integrins (42).
Binding of FN9-11 is specific as it can be inhibited by EDTA or function blocking anti-α5β1 antibodies and stimulated by the β1-activating antibody, 9EG7, and Mn ++ (data not shown). Using this approach, we found that Tac-β3, but not Tac-β3(W739A), Tac-β3(L746A,K748A) or Tac-β3(L746A) inhibited activation of endogenous hamster α5β1A (Fig 3C) . Thus, integrin β tails require an intact talin-binding site to mediate trans-dominant inhibition of a variety of β1 and β3 integrins. along with Tac-β3 reversed trans-dominant suppression of both αIIbβ3 and αIIbα5β3
Over-expression of the integrin-binding domain of talin reverses
integrins (Fig 4) , supporting the hypothesis that competition for talin mediates transdominant inhibition of integrin activation. 
Expression of talin-binding variants of
Suppression of activation was not dependent on the kinase activity of PIPKIγ-90
as PIPKIγ-90 containing a point mutation (K138A) that inhibits kinase activity (49) is still capable of inhibiting integrin activation (Fig. 5A, B) . However, a Trp 647 to Phe point mutation within the PIPKIγ-90 talin-binding sequence, which inhibits talin binding (41), prevented inhibition of integrin activation (Fig. 5A) . The differing effects of the PIPKIγ variants were not due to differing expression levels as analyses were performed on cells gated for similar GFP expression and western blotting of cell lysates revealed that all the GFP-fusions were intact (Fig 5C) . Thus, PIPKIγ-90 can inhibit integrin activation in a manner analogous to the trans-dominant inhibition by free integrin β tails.
Trans-dominant inhibition of cell spreading requires an intact talin-binding site in the
suppressive species. The results described above indicate that competition for talin results in trans-dominant inhibition of integrin activation. Expression of isolated β tails or of PIPKIγ-90 also produces a dose-dependent inhibition of cell spreading (40;41;52).
In the case of PIPKIγ-90, inhibition of spreading is dependent a functional talin-binding site within the PIPKIγ protein (41) . In order to test whether talin binding to the isolated integrin β tail is required for trans-dominant inhibition of cell spreading we expressed Tac-α5, Tac-β3, Tac-β3(W739A) or Tac-β3(L746A,K748A) in αIIbβ3-expressing CHO cells and assessed the ability of these cells to spread on fibrinogen. Cells expressing Tac-β3 spread significantly less than those expressing Tac-α5, Tac-β3(W739A) or Tac-β3(L746A,K748A) (T-test two tailed p< 10 -4 ) (Fig 5) . Thus, talin binding to the suppressive isolated β tails or to over-expressed PIPKIγ-90, is required for transdominant inhibition of integrin activation and cell spreading.
Discussion
Crosstalk between different integrins and between integrins and other receptors impacts many essential cellular processes including adhesion, migration, proliferation and matrix assembly (19) . Here we report that competition for talin underlies one form of integrin crosstalk, trans-dominant inhibition of integrin activation. This conclusion is based on our observations that (i) free integrin β tails selectively defective in talin binding are Src-family kinases may also be involved in modulating competition for talin between integrins and so influence trans-dominant inhibition. Integrin cytoplasmic tails can be tyrosine phosphorylated by Src leading to reduced talin binding (51;64) .
Therefore differential phosphorylation of integrin tails will influence their ability to compete for talin, in this regard it is noteworthy that integrin β tails show differential specificities for interaction with Src-family kinases (65) .
The vital role of integrin-talin interactions in integrin function suggested that regulation of these interactions provides a mechanism to control integrin function (1;3).
The results presented here indicate that one mechanism by which such regulation can be 
